Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients
Status:
Unknown status
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
Comparing intermediate-dose CTX (ID-CTX)and G-CSF with rhTPO or without for peripheral blood
stem cell mobilization in patients with multiple myeloma, try to find out whether rhTPO
combined to ID-CTX + G-CSF could improve the results of peripheral blood stem cell
mobilization.